A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3549492 Once Daily Compared With Placebo in Adult Participants With Obesity or Overweight
Latest Information Update: 25 Apr 2025
At a glance
- Drugs LY 3549492 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 22 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2024 Status changed from not yet recruiting to recruiting.
- 14 Nov 2024 New trial record